1

18/04/23

Decision-making on FP7 work

programmes and calls

European CommissionResearch and Inovation DG,

Directorate F HealthGrigorij Kogan

EKHA Meeting, Brussels 23/01/2012

2

18/04/23

EU supportfor Research and Innovation

The €50 billion Seventh Framework Programme (FP7, 2007-2013) supports basic and applied research activities, still far from the market, offers money and concentrates resources on strategic research areas, always on the basis of technological and scientific excellence.

The broad objectives of FP7 have been grouped into four categories: Cooperation IdeasPeopleCapacities For each type of objective, there is a specific programme corresponding to the main areas of EU research policy. All specific programmes work together to promote and encourage the creation of European poles of (scientific) excellence

3

18/04/23

FP7 budget (2007-2013): €55 billion

= ~6% of public R&D investment in Europe

4

18/04/23

Cooperation programme:thematic areas (€32.4 billion)

5

18/04/23

http://bookshop.europa.eu/eubookshop/publicationDetails.action?pubuid=593335&offset=0

6

18/04/23

FP7 Health Programme - structure

pillar 1:Biotechnolog

y, generic tools

& technologies for health

pillar 3:Optimising the delivery

of health care

cross-cutting issues: child health, the health of ageing population gender-related health issues

pillar 2:Translating research for

human health

Activity (Pillar) 4: Other actions across the theme

7

18/04/23

Collaborative researchin the Health theme

Main policy drivers: Improving health of European citizens

Increasing competitiveness of European health-related industries and businesses

Addressing global health issues, including emerging epidemics

8

18/04/23

Collaborative research at European level

across borders and other barriers● between countries:

multinational consortia, with at least 3 partners from 27 EU Member States (MS) and / or Associated Countries (AC) e.g.: Albania, Croatia, FYR Macedonia, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey.

researchers from any country in the world can participate, from industrialised countries and from developing countries. e.g.: Argentina, Australia, Brazil, Canada, China, India, Japan, Korea, New-Zealand, Russia, South-Africa, USA…

● between different types of organizationsPublic & private sector: universities, research centres, large companies, Small and medium-sized enterprises (SMEs), etc.

● between disciplines: multidisciplinary, translational

9

18/04/23

Collaborative researchin the Health theme

1: Biotechnology, generic tools and technologies

High-throughput research

Detection, diagnosis and monitoring

Predicting suitability, safety and efficacy of therapies

Innovative therapeutic approaches and interventions

10

18/04/23

Collaborative researchin the Health theme

2: Translating research for human health

Integrating biological data and processes:

large-scale data gathering, systems biology

Research on the brain and related diseases, human development and ageing

Translational research in major infectious diseases

Translational research in other major diseases

11

18/04/23

Collaborative researchin the Health theme

3: Optimising the delivery of healthcare

Translating clinical research into clinical practice

Quality, efficiency and solidarity of healthcare systems

Enhanced health promotion and disease prevention

12

18/04/23

4. Actions across the Theme

Coordination & Support Actions across the theme

Responding to EU policy needs

Specific International Cooperation Actions (SICAs)

Collaborative researchin the Health theme

13

18/04/2318/04/23

FP7 Cooperation Work Programme: Health-2012

14

18/04/23

Two-stage submission and evaluation procedure

Timetable

Publication of call FP7-HEALTH-2012-INNOVATION-2 20 July 2011

Deadline for submission of stage 1 outline proposals 27 September 2011

Evaluation of stage 1 outline proposals October 2011

ESRs sent to outline proposal coordinators (“initial information letters”, including invitation letters to successful applicants)

November 4, 2011

Deadline for submission of stage 2 full proposals 13 December 2011

Evaluation of stage 2 full proposals January 2012

Ethical screening By February 3, 2012

Invitation letter to successful coordinators to launch grant agreement negotiations with Commission services

By February , 2012

Negotiation kick-off meeting in Brussels February 13, 2012

Signature of first grant agreements April 2012

15

18/04/23

Funding schemes in the Health theme

Funding schemes limits partners

Large-scale integrating project (CP-IP) ≥ €6m ≤ €12m ≥3

Network of Excellence (NoE) ≤ €12m ≥3

Small- or medium-scale focussed research project (CP-FP) ≤ €3m or €6m ≥3

Coordination action (CA)* ≤ €1.5m ≥3

Support action (SA)* ≤ €0.5m ≥1

* for CAs and SAs there are some exceptions.

16

18/04/23

Emphasis and special measures for:

Small & Medium-sized Enterprises (SMEs) Opportunities and support measures

International Cooperation

the possibility to tackle issues on a global scale

an opportunity to extend networks beyond Europe

Policy dimensions: Industry (SME) participation

& International Cooperation

17

18/04/23

Who prepares the work programmes for the Research Priorities● The EU Commission

Collects ideas for the preparation of the annual FP7 work program Drafts the (annual) FP7 work plans Within the EU Commission Scientific Officers (SO) are responsible for

the preparatory worko Advisory Groups (AG) Have been set up by the EU Commission for each of the FP7 themes They provide consistent, consolidated advice for the work program Members sit on the AG in their personal capacity and do not represent

any organisation or countryo National Contact Points (NCPs) Are main providers of advice and individual assistance in all Member

States and Associated States Have been set up by the Member or Associated States so the type and

level of services offered may differ from country to countryo Programme Committees (PCs) Play an important role at the end of the preparation process of each

work program. They have to give their approval for all the work programmes that

have been prepared by he EU Commission. Are involved quite early in the preparation process to insure that the

preparation procedure works quick and smooth

18

18/04/23

Scientific excellence at European level

From policy to funding the best research projects:

● The policy for Health research is described in the FP7 specific programme (available on CORDIS http://cordis.europa.eu/home_en.html)

● Each year, a work programme is prepared by the EC, in consultation with a scientific Advisory Group and with the Programme Committee

● Through calls for proposals the EC invites researchers from all Europe and beyond to submit their proposals

● The very best projects are selected on the basis of evaluation by independent experts (peer review)

● After negotiation of a grant agreement, a project is funded for 2-5 years

19

18/04/23

Submission & evaluation

Basic principles:

annual calls for proposals

eligibility (scope, partners, funding limits, deadline)

evaluation by panels of independent experts

overseen by Independent Observers

3 criteria: Science & Technology excellence Implementation & Management Potential Impact

feedback: Evaluation Summary Reports (ESRs)

20

18/04/23

Annual calls for proposals

in the Health Theme

€ 0

€ 200

€ 400

€ 600

€ 800

1st call -2007

2nd call -2008

3rd call -2009

4th call -2010

5th call -2011

6th call -2012

7th call -2013

Call

Budget (m

illion)

1st call (2007 budget): € 641 million

2nd call (2008 budget): € 577 million

3rd call (2009 budget): € 610 million

4th call (2010 budget): € 660 million

5th call (2011 budget): € 650 million

6th call (2012 budget): ~ € 645 million

7th call (2013 budget): ~

21

18/04/23

21

The Innovative Medicines Initiative (IMI):the Largest PPP in Life Sciences R&D

Why Public-Private Partnership?• Innovative medicines require in-depth knowledge of disease pathways and molecular targets• Anticipating potential side effects of new drugs is a must• The pharmaceutical industry builds new business models based on collaboration and transparency

Key Concepts Underlying IMI Projects:• Pre-competitive research• Open innovation

http://www.imi.europa.eu/

Four Calls published since 2008:• 23 projects funded• Over € 450 million committed

22

18/04/23

Coverage of Kidney Diseases in FP7

Pillar IDEAS – ERC (European Research Council): 4 projects with € 6,813,200 EU Contribution

Pillar COOPERATION -HEALTH: 7 projects with € 46,188,148 EU ContributionINFSO: 2 projects with € 8,759,140 EU Contribution

Pillar PEOPLE – 13 projects with € 9,872,575 EU Contribution

Total EU Contribution - € 71,633,063

23

18/04/23

24

18/04/23

Contacts & Information

FP7 Health web site: http://cordis.europa.eu/fp7/health

NCPs: http://cordis.europa.eu/fp7/health/support_en.htmlRegistration as an Expert: https://cordis.europa.eu/emmfp7/

FP7 calls: http://cordis.europa.eu/fp7/dc

Health projects database: www.healthcompetence.eu

SMEsgoHealth: www.smesgohealth.org

25

18/04/23

The Health DirectorateDirector – Dr. Ruxandra Draghia-Akli:

Medical Research unit (F2)Head of unit: Maria Vidal-Ragout (maria-jose.vidal-ragout@ec.europa.eu)Deputy Head of Unit: Karim Berkouk (karim.berkouk@ec.europa.eu)Infectious Diseases unit (F3) Head of unit: Line Mathiessen (line.mathiessen@ec.europa.eu)Deputy Head of unit: Anna Lönnroth (anna.lonnroth@ec.europa.eu) Avanced Therapies and Systems Medicine unit (F4)Head of unit: Arnd Hoeveler (arnd.hoeveler@ec.europa.eu)Deputy Head of unit: Bernard Mulligan (bernard.mulligan@ec.europa.eu)

Personalized Medicine unit (F5) Head of unit: Patrik Kolar (patrik.kolar@ec.europa.eu)Deputy Head of unit: Irene Norstedt (irene.norstedt@ec.europa.eu)Administration & Finance unit (F6)

Head of unit: Georgios Zisimatos(georgios.zisimatos@ec.europa.eu)

Horizontal Aspects unit (F1) Head of unit: Stéphane Hogan (stephane.hogan@ec.europa.eu)

26

18/04/23

What is Horizon 2020

27

18/04/23

THANK YOU FOR YOUR ATTENTION!

Grigorij Kogan « Chronic Diseases »Unit F-2 Medical ResearchDirectorate F « Health »

DG Research and InnovationEuropean Commissiongrigorij.kogan@ec.europa.eu